
WVE Stock Forecast & Price Target
WVE Analyst Ratings
Bulls say
WAVE Life Sciences Ltd is focused on advancing its RNA medicines platform, PRISM, which has shown potential through positive data in various programs targeting diseases like obesity and Duchenne muscular dystrophy. The anticipated initial data from the Phase 1 study of WVE-007 is expected to demonstrate significant efficacy in weight reduction and body composition improvement, coupled with a favorable safety profile, reinforcing the company’s capabilities in RNA editing. Collectively, these developments suggest a strong validation of WAVE’s innovative platform and its potential to deliver differentiated, best-in-class therapies in the RNA editing landscape.
Bears say
WAVE Life Sciences Ltd faces significant risks that could negatively impact its financial outlook, including the potential failure of key clinical studies such as WVE-004 and WVE-N531, which are crucial for the company's pipeline. Additionally, the inability to secure regulatory approval for these treatments poses a major hurdle that could thwart anticipated revenue generation from their product candidates. Lastly, the current data suggests challenges in achieving peak commercial revenue estimates for WVE-003 and WVE-N531, potentially due to limitations in market size, penetration, and pricing strategies.
This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
WVE Analyst Forecast & Price Prediction
Start investing in WVE
Order type
Buy in
Order amount
Est. shares
0 shares